News / 30.08.2019

The Haavind Pharma Report Summer 2019

Author(s) Håkon Austdal & Vebjørn Krag Iversen

In the Pharma Report Summer 2019, we take a retrospective look at some of the legal developments during the first half of 2019 in the Norwegian pharmaceutical sector.

The first half of 2019 has been an interesting year for legal practitioners working in the pharmaceutical sector. While there has been less litigation so far, the first 6 months has nevertheless been interesting, particularly from a regulatory viewpoint.

In this edition of our biannual report, you can read about the latest developments on off-label use of medicinal products in Norway. You can also read about the latest amendments in patent legislation, which entered into force in July 2019, as well as the development concerning transparency on both prices of medicinal products and disclosure of payments to healthcare professionals.

Haavind Pharma Report Summer

Haavind’s Health and Life Science team continuously and closely monitors developments in Norway relevant to the pharma sector. If you wish to discuss how your business can best meet the legal challenges of this innovative and highly regulated sector, you are always welcome to contact us.

  • Håkon Austdal

    Senior Associate

    Håkon Austdal is specialised in intellectual property rights, marketing law and regulatory legislation within food law, pharmaceuticals and life sciences. He assists Norwegian and foreign enterprises within the areas food, pharmaceuticals and life sciences with questions concerning advertising, labelling and regulatory affairs.

  • Vebjørn Krag Iversen


    Vebjørn specialises in intellectual property (IPR) and media law. He has extensive experience from patent litigation in the pharmaceutical industry, agreements on technology development and licensing, know-how / trade secrets, agreements on research and technology development, enforcement of trademark rights, copyright issues and counseling.